- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.09. | Hansa eyes speedy FDA review after posting ph. 3 win for kidney transplant drug | ||
| 25.09. | With SCOTUS appeal, AstraZeneca makes last-gasp challenge against Medicare price negotiation program | ||
| 25.09. | BMS plots another DTC platform, this one offering Sotyktu at 80% discount to cash-pay patients | ||
| 25.09. | FDA takes close look at mifepristone REMS program after request from Republican AGs | ||
| 25.09. | Merck KGaA, grappling with geopolitical tensions, names new CEO | ||
| 25.09. | Moderna crowns new UK facility as other drugmakers pile on the kingdom | ||
| 25.09. | Guardant backs ALA's lung cancer testing awareness drive | ||
| 24.09. | Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno | ||
| 24.09. | Fujifilm Biotechnologies cuts ribbon on $3.2B antibody facility in NC | ||
| 24.09. | Generics makers to sell Gilead's Yeztugo at $40 a year under deals with Gates Foundation, others | ||
| 24.09. | Big Pharma's backlash against Britain continues as Lilly CEO Ricks blasts UK on drug pricing, investment | ||
| 24.09. | Vertex secures all-star assist for Journavx, signing up NBA's Jayson Tatum for pain drug promotion | ||
| 24.09. | In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu | ||
| 24.09. | Biogen plots resubmission after FDA turns down high-dose Spinraza in SMA, requests more production info | ||
| 23.09. | Trust, satisfaction in pharma slipping among Gen Z, millennials: survey | ||
| 23.09. | FDA hands warning letter to J&J vaccine subsidiary over stopper issues, spotty reporting at Korean plant | ||
| 23.09. | Eli Lilly picks Houston to build $6.5B API manufacturing facility | ||
| 23.09. | Sobi surpasses Roche in rare disease patient groups' reputation rankings | ||
| 23.09. | Moderna says updated mNEXSPIKE induces strong immune response against rising COVID-19 strain | ||
| 23.09. | Celltrion snaps up Lilly's N.J. drug substance plant for $330M in tariff mitigation move, pledges to retain employees | ||
| 23.09. | Catalent moves into new global HQ as Novo sale nears one-year anniversary | ||
| 23.09. | FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site | ||
| 22.09. | FDA turns down Lundbeck, Otsuka's Rexulti in PTSD on lack of efficacy data | ||
| 22.09. | In Trump's 'answer' to autism, health officials to warn against Tylenol during pregnancy, propose potential treatment: WaPo | ||
| 22.09. | In UK, Big Pharma pressure campaign rolls on as Bristol Myers plans US-level pricing for Cobenfy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .